Meanwhile, the inhibition of the GHKL-ATPase activity of MORC2 enhanced the sensitivity of HCC cells to sorafenib by regulating the Hippo signaling pathway,78 suggesting that inhibition of targeted GHKL-ATPase activity of MORC2 is a promising strategy to prevent chemotherapy resistance. This evidence concerns the gene MORC2 and hepatocellular carcinoma.